Opzelura access guide: country options for cross-border named-patient access

Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

About Opzelura

Opzelura (ruxolitinib (topical cream)) is a Janus kinase (JAK1 and JAK2) inhibitor, topical formulation approved by the US Food and Drug Administration for atopic dermatitis and non-segmental vitiligo in patients aged 12 years and older. The current FDA label is available at accessdata.fda.gov. Opzelura is marketed by Incyte. Reserve Meds coordinates US-sourced cross-border access to Opzelura under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Opzelura in each jurisdiction Reserve Meds has authored.

Opzelura country-specific access guides

Reserve Meds has published 3 country-specific access guides for Opzelura. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.

Other countries not yet authored

Reserve Meds has authored country-specific access guides for Opzelura in the 3 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Opzelura. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.

Request a Opzelura access scope for your country

Related Reserve Meds resources

• Access pathways index (named-patient, personal-import, hospital-exemption, and equivalent frameworks by country)
• Conditions index (the indication families Reserve Meds coordinates around)
• Drug catalog (all FDA-labeled medicines in the Reserve Meds coordination scope)
• All country-specific access guides
• How Reserve Meds coordinates a cross-border case
• Trust, compliance, and editorial review

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.

Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.